A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections
Participants who have agreed to receive epcoritamab treatment according to the latest approved local label or have already started epcoritamab treatment as per the approved label information at the time of the first administration of epcoritamab.
Participants who voluntarily agree to participate in this study and sign informed consent.
You may not be if
Contraindication to epcoritamab as listed on the latest approved local label.
Currently participating in another clinical research except observational study.
Clareo Health | A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections
